American Association for Cancer Research
10780432ccr211023-sup-262635_3_supp_7268839_qwjbz6.docx (15.77 kB)

Table S2 from The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor–Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8

Download (15.77 kB)
journal contribution
posted on 2023-03-31, 22:42 authored by Martin Filipits, Margaretha Rudas, Verena Kainz, Christian F. Singer, Florian Fitzal, Zsuzsanna Bago-Horvath, Richard Greil, Marija Balic, Peter Regitnig, Stefan Halper, Wolfgang Hulla, Daniel Egle, Stephen Barron, Tony Loughman, Des O'Leary, William M. Gallagher, Dominik Hlauschek, Michael Gnant, Peter Dubsky

Cross-study analysis between Prosigna® and OncoMasTR


OncoMark Ltd

European Union's Horizon 2020 research



To validate the clinical performance of the OncoMasTR Risk Score in the biomarker cohort of Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 8. We evaluated the OncoMasTR test in 1,200 formalin-fixed, paraffin-embedded (FFPE) surgical specimens from postmenopausal women with estrogen receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative primary breast cancer with 0 to 3 involved lymph nodes in the prospective, randomized ABCSG Trial 8. Time to distant recurrence (DR) was analyzed by Cox models. The OncoMasTR Risk Score categorized 850 of 1,087 (78.2%) evaluable patients as “low risk”. At 10 years, the DR rate for patients in the low-risk group was 5.8% versus 21.1% for patients in the high-risk group (P < 0.0001, absolute risk reduction 15.3%). The OncoMasTR Risk Score was highly prognostic for prediction of DR in years 0 to 10 in all patients [HR 1.91, 95% confidence interval (CI) 1.62–2.26, P < 0.0001; C-index 0.73], in patients that were node negative (HR 1.79, 95% CI, 1.43–2.24, P < 0.0001; C-index 0.72), and in patients with 1 to 3 involved lymph nodes (HR 1.93, 95% CI, 1.44–2.58, P < 0.0001; C-index 0.71). The OncoMasTR Risk Score provided significant additional prognostic information beyond clinical parameters, Ki67, Nottingham Prognostic Index, and Clinical Treatment Score. OncoMasTR Risk Score is highly prognostic for DR in postmenopausal women with ER-positive, HER2-negative primary breast cancer with 0 to 3 involved lymph nodes. In combination with prior validation studies, this fully independent validation in ABCSG Trial 8 provides level 1B evidence for the prognostic capability of the OncoMasTR Risk Score.

Usage metrics

    Clinical Cancer Research



    Ref. manager